Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065451 | 0.87 | GAA (0.47) | GAATHRBCCR2CYP1A2CYP3A4 | |
| SCHEMBL719799 | 0.86 | CCR2 (0.58) | GAACCR2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2987304 | 0.86 | GAA (0.46) | GAATHRBCCR2CYP1A2CYP3A4 | |
| SCHEMBL3259739 | 0.81 | CCR2 (0.69) | GAATHRBCCR2P2RX7KDM4E | |
| SCHEMBL3316845 | 0.79 | ALOX15 (0.44) | GAACCR2P2RX7SMN1; SMN2MEN1 | |
| SCHEMBL5172985 | 0.79 | ALOX15 (0.44) | GAACCR2P2RX7SMN1; SMN2MEN1 | |
| SCHEMBL13013126 | 0.78 | CCR2 (0.75) | GAATHRBCCR2KDM4ESMN1; SMN2 | |
| SCHEMBL3318233 | 0.76 | HPGD (0.37) | GAACCR2SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL3744094 | 0.74 | GAA (0.36) | GAATHRB | |
| SCHEMBL3316925 | 0.71 | CCR2 (0.60) | CCR2P2RX7SMN1; SMN2EPHX1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497261-B2 | 3-aminocaprolactam compounds for treating inflammatory disorders | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-30 | — | — | US | claimed |
| US-20100292213-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-11-18 | — | — | US | claimed |
| US-7691845-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-04-06 | — | — | US | claimed |
| US-20080194541-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2008-08-14 | — | — | US | claimed |
| US-8497261-B2 | 3-aminocaprolactam compounds for treating inflammatory disorders | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-30 | — | — | US | disclosed |
| EP-1781299-B1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2010-12-22 | — | — | EP | disclosed |
| US-20100292213-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-11-18 | — | — | US | disclosed |
| EP-2229184-A2 | ANTI-INFLAMMATORY COMPOSITIONS AND COMBINATIONS | Cambridge Enterprise Ltd. (GB) | 2010-09-22 | — | — | EP | disclosed |
| US-7691845-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| WO-2009074794-A2 | ANTI-INFLAMMATORY COMPOSITIONS AND COMBINATIONS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| US-20080194541-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194541-A1 | Anti-Inflammatory Agents | TNF, IL1RN, FPR1 | GAA 1896/4885THRB 4810/4885CCR2 96/4885 |
| US-20100292213-A1 | Anti-Inflammatory Agents | TNF, IL1RN, IL1R1 | GAA 1878/4885THRB 4799/4885CCR2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.